Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

Lancet

Volumn 369, Issue 9569, 2007, Pages 1261-1269

  Grinsztejn, Beatriz ^a   Nguyen, Bach Yen ^b   Katlama, Christine ^c   Gatell, Jose M ^d   Lazzarin, Adriano ^e   Vittecoq, Daniel ^f   Gonzalez, Charles J ^g   Chen, Joshua ^b   Harvey, Charlotte M ^b   Isaacs, Robin D ^b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF BARCELONA   (Spain)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f HÔPITAL PAUL BROUSSE   (France)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ATAZANAVIR; ENFUVIRTIDE; INDINAVIR; INTEGRASE INHIBITOR; MK 0518; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; BRADYCARDIA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEART ARREST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INJECTION SITE REACTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MULTICENTER STUDY; MULTIDRUG RESISTANCE; NAUSEA; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RNA VIRUS; SEPSIS; SIDE EFFECT; SUICIDE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; VOMITING;

EID: 34147136222     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60597-2     Document Type: Article

References (22)

1. Young B., Carmichael J., Johnson D., and Mills T. PA update: DHHS guidelines for the treatment of HIV infection. JAAPA suppl 1 (2006) 3-13
2. Hammer S., Saag M., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 296 (2006) 827-843
3. DHHS Panel-Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2006), US Department of Health and Human Services, Washington, DC
4. De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs 10 (2005) 241-273
5. de Bethune M., and Hertogs K. Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance. Curr Med Res Opin 22 (2006) 2603-2612
6. Machouf N., Thomas R., Nguyen V., et al. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol 78 (2006) 608-613
7. Tozzi V., Zaccarelli M., Bonfigli S., et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients therapy: prevalence, risk factors and virological outcome. Antivir Ther 11 (2006) 553-560
8. Gulick R. New antiretroviral drugs. Clin Microbiol Infect 9 (2003) 186-193
9. Richman D., Morton S., Wrin T., et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
10. Couto-Fernandez J., Silva-de-Jesus C., Veloso V., et al. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 100 (2005) 73-78
11. Hazuda D., Felock P., Witmer M., et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287 (2000) 646-650
12. Miller M, Witmer M, Stillmock K, et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor. 16th International AIDS Conference; Toronto, Canada, Aug 13-18, 2006. Abstract THAA0302.
13. Markowitz M., Morales-Ramirez J., Nguyen B.-Y., et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 43 (2006) 509-515
14. Markowitz M, Nguyen B-Y, Gotuzzo F, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment naive HIV-1 infected patients. 16th International AIDS Conference; Toronto, Canada; Aug 13-18, 2006. Abstract THLB0214.
15. Mistry GC, Wenning LA, Merschman S, et al. Atazanavir and ritonavir increase plasma levels of MK-0518. 8th International Congress on Drug Therapy in HIV Infection; Glasgow, UK; Nov 12-16, 2006. Abstract P291.
16. Hicks C., Cahn P., Cooper D., et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368 (2006) 466-475
17. Lalezari J., Henry K., O'Hearn M., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348 (2003) 2175-2185
18. Lazzarin A., Clotet B., Cooper D., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348 (2003) 2186-2195
19. Kassahun K, McIntosh I, Hreniuk D, et al. Absorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; Sept 27-30, 2006. Abstract A372.
20. Wenning LA, Hanley W, Stone J, et al. Effect of tipranavir + ritonavir (TPV + RTV) on pharmacokinetics of MK-0518. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; Sept 27-30, 2006. Abstract A374.
21. Wenning LA, Friedman E, Kost JT, et al. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF). 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; Sept 27-30, 2006. Abstract A375.
22. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of MK-0518. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; Sept 27-30, 2006. Abstract A373.